VANCOUVER, BC, March 8, 2022 /PRNewswire/ - Apex Labs Ltd. ("Apex", or the "Company"), a socially focused pharmaceutical company, is pleased to announce the receipt of a No Objection Letter ("NOL") ...
APEX-002-A01-02 will evaluate the safety and efficacy of APEX-52 low dose, multi-dose synthetic psilocybin drug product in treating depression in Veterans with PTSD VANCOUVER, BC, Nov. 1, 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results